TrialJournal for immunotherapy of cancer2025

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.

Matthew S Block et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.